Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16709120 | 0.88 | CSNK1E (0.36) | ALOX5APFEN1APPRORCCYP3A4 | |
| SCHEMBL16711541 | 0.87 | BTK (0.36) | RET | |
| SCHEMBL16709116 | 0.83 | KAT5 (0.35) | APPKAT6AKAT5CYP3A4CYP3A5 | |
| SCHEMBL16709131 | 0.82 | CSNK1E (0.36) | RORCKAT5CYP3A4CYP3A5HDAC8 | |
| SCHEMBL16709129 | 0.76 | CSNK1E (0.44) | — | |
| SCHEMBL16709126 | 0.76 | CNR1 (0.36) | KAT6AKAT5CYP3A4CYP3A5P2RX7 | |
| SCHEMBL16711392 | 0.75 | CSNK1E (0.40) | RET | |
| SCHEMBL16709119 | 0.75 | KAT5 (0.35) | RORCKAT6AKAT5CYP3A4CYP3A5 | |
| SCHEMBL16709101 | 0.74 | CSNK1E (0.36) | ALOX5APFEN1CDK9APPCYP3A4 | |
| SCHEMBL16711542 | 0.74 | CSNK1E (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | ALOX5AP 4509/4885FEN1 2896/4885CDK9 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.